Recently, the Hong Kong-listed company Huanjian Medical announced significant news, as it has established a wholly-owned subsidiary IVD GROUP in New York, USA. This move marks the official launch of Huanjian Medical's strategic layout in the US market, laying a solid foundation for the implementation of the IVDNewCo Exchange project.

It is worth noting that IVD GROUP has begun applying for a stablecoin license from relevant regulatory authorities in the United States. This process involves several important regulatory agencies, including the U.S. Securities and Exchange Commission (SEC) and the Commodity Futures Trading Commission (CFTC). This move not only reflects Huajian Medical's forward-looking vision in the global compliance field but also demonstrates the company's efficient decision-making and action in executing its international strategy.

Huajian Medical previously stated its plan to apply for a US stablecoin license, and today's actions are a fulfillment of that prior commitment. This series of actions reflects the company's ambitions in the global fintech field, while also highlighting its determination to seek compliant development in the international market.

With the establishment of IVD GROUP and the initiation of the stablecoin license application, the industry generally believes that Huajian Medical is actively preparing to enter the international fintech market. This could not only bring new business growth opportunities for the company but also enhance its competitiveness and influence in the global market.

The initiative by Huajian Medical has attracted widespread attention in the market, with many analysts believing that this may indicate that more Chinese companies will actively participate in global financial technology innovation, while also reflecting the high importance that enterprises place on compliance in the process of internationalization. In the future, the development trends of Huajian Medical in the US market will undoubtedly become the focus of industry attention.